

Human PD1 (epitope 2)



www.mesoscale.com®

Ordering Information

MSD Customer Service Phone: 1-240-314-2795 : 1-301-990-2776 Email: CustomerService@ mesoscale.com

Scientific Support

Phone: 1-240-314-2798 Email: ScientificSupport@ mesoscale.com


Company Address

MESO SCALE DISCOVERY®
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description	
Multiplex	K151AEM, K251AEM	U-PLEX Immuno-Oncology Group 1 (human)	
	K151V7K-1/-2/-4	U-PLEX Human PD1 (epitope 2) Assay with SECTOR™ plates	
Singleplex	K151V7K-21/-22/-24	U-PLEX Human PD1 (epitope 2) Assay with QuickPlex® plates	
	K251V7K-2/-4	U-PLEX Human PD1 (epitope 2) Assay with 384-well plates	
Antibody Set	B22V7-2/-3	U-PLEX Human PD1 (epitope 2) Antibody Set	
Protocol	U-PLEX Product Inserts are available at www.mesoscale.com		

The U-PLEX® platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX Human PD1 (epitope 2) Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available on 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)	
PD1 (epitope 2)	0.11	0.09-0.19	

The Calibrator curve was fitted with a 4-parameter logistic model with a $1/Y^2$ weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5 standard deviations above the background (zero Calibrator).


Precision

Control	Average Conc. (pg/mL)	Average Intra-run Conc. (%CV)	Inter-run Conc. (%CV)
High	255	3.7	4.8
Mid	47	5.4	3.7
Low	7.7	9.0	3.3

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

Note: PD1 (epitope 2) is significantly impacted by Nivolumab (Opdivo) and by Pembrolizumab (Keytruda). PD1 (epitope 1) is not affected by these therapeutic antibodies.

For Research Use Only. Not for use in diagnostic procedures.





MSD® U-PLEX Human PD1 (epitope 2)

Tested Samples

Sample Type	Serum (N=10)	Normal Lysate (N=5)	Tumor Lysate (N=5)	
Median (pg/mL)	166	37	74	
Range (pg/mL)	140-223	10-125	5.3-513	
% Detected	100	100	100	

Normal serum and plasma samples were diluted 4-fold prior to the assay. Lysates were tested at a protein concentration of 0.5 mg/mL.

Dilution Linearity

Serum			EDTA Plasma		
Fold Dilution		% Recovery Range	Fold Dilution		% Recovery Range
2	96	90 - 102	2	96	92 - 97
8	103	101 - 108	8	100	96 - 103
16	104	96 - 114	16	101	96 - 109

Normal human serum and EDTA plasma were spiked with Calibrator and tested at different dilutions. Percent recovery at each dilution level was normalized to the dilutionadjusted, 4-fold concentration. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Spike Recovery

	Serum		EDTA I	Plasma
Spike Level	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
High	112	106 - 122	109	97 - 116
Mid	101	58 - 122	116	106 - 122
Low	136	105 - 209	114	108 - 119

Normal serum and plasma were spiked with Calibrator at 3 levels. Spiked samples were diluted 4-fold to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Specificity

To assess specificity, the PD1 (epitope 2) Antibody Set was tested individually against a larger panel of analytes for nonspecific binding: APRIL/TNFSF13, BAFF-R/TNFRSF13C, BCMA/TNFRSF17, CD20, CD27, CD276/B7-H3, CD28, CD40L (soluble), CTACK, CTLA-4, ENA-78, Eotaxin, Eotaxin-2, Eotaxin-3, EPO, E-Selectin, FGF (basic), FLT3L, Fractalkine, G-CSF, Galectin-9, GITR/TNFRSF18, GITRL/TNFSF18, GM-CSF, gp130 (soluble), Granzyme A, Granzyme B, GR0- α , HAVCR2/TIM-3, HVEM/TNFRSF14, I-309, ICOS, ICOSL/B7-H2, IFN- α 2a, IFN- β , IFN- γ , IL-1 α , IL-1 β , IL-1RA, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17C, IL-17D, IL-17E/IL 25, IL-17F, IL-18, IL-2, IL-21, IL-22, IL-23, IL-27, IL-29/IFN- α 1, IL-2R α 1, IL-3R, IL-31, IL-31, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, I-TAC, LAG-3, LIGHT/TNFSF14, MCP-1, MCP-2, MCP-4, M-CSF, MDC, MIF, MIG, MIP-1 α 1, MIP-5, MMP-1, MMP-2, MMP-7, MMP-9, Nectin-4, 0X40/TNFRSF4, PD1, PD-L1, PD-L2, Pentraxin 3, Perforin, PIGF, P-Selectin, RAGE (soluble), RANKL/TNFSF11, RANTES, S100A12, SDF-1 α 1, TARC, Tie-2, TIGIT, TLR-1, TNF-RI, TNF-RI, TNF- α 3, TNF- α 5, TP0, TRAIL, TSLP, VEGF-A, VEGF-D, VEGFR-1/Fit-1 and YKL-40. Nonspecific binding was less than 2.0%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

PD1 (epitope 2) assay should not be combined with PD1 (epitope 1) assay in the same plate.

Diluent Compatibility

Diluents 58 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: PD1 is included in Calibrator 20 The human PD1 Calibrator is PD1 (25–168) expressed in a human cell line.

Antibodies: The U-PLEX Human PD1 (epitope 2) Assay uses a mouse monoclonal antibody for capture and a mouse monoclonal antibody for detection.

Assay generation: A

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently from the representative data shown.



